Enhanced Launches Prescription Topical Peptide, Expanding Telehealth Platform
Event summary
- Enhanced has launched a prescription topical GHK-Cu cream, priced at $119 per month with auto-refill.
- The product delivers a consistent 10mg dose of GHK-Cu per application, dispensed via the Live Enhanced telehealth platform.
- This marks Enhanced’s first prescription topical product, extending their offerings beyond injectables like Sermorelin.
- The formulation was developed under the oversight of Enhanced's Medical Commission and is differentiated by its milligram-specific dosing.
The big picture
Enhanced is strategically positioning itself as a leader in the emerging ‘Performance Medicine’ category by leveraging telehealth to deliver prescription-grade peptides directly to consumers. This move represents a shift away from purely over-the-counter supplements and towards a more personalized, clinically-guided approach to longevity and performance enhancement. The company’s focus on precise dosing and medical oversight differentiates it from the broader, often unregulated, market for topical peptides.
What we're watching
- Platform Adoption
- The success of this launch hinges on Enhanced’s ability to drive clinician adoption and patient engagement within its telehealth platform, as the product requires a consultation.
- Regulatory Scrutiny
- As Enhanced expands into prescription products, increased regulatory scrutiny regarding product safety, efficacy claims, and telehealth practices is likely.
- Competitive Response
- The introduction of a prescription topical GHK-Cu will likely draw responses from both established cosmetic brands and other telehealth providers entering the peptide space.
Related topics